Dogma Biotech Wins $100K Award from QB3 Mentoring Program to Develop Glycosylation Technology for Biologics - QB3
Summary
Dogma Biotech won a $100K award from QB3’s mentoring program to advance its glycosylation technology for biologic drugs. The company develops precision glycosylation methods that aim to improve tissue targeting, reduce immune reactions, and lower side effects. It plans to use the award to establish scientific operations in the Bay Area and deepen relationships with investors and partners. The company also intends to continue proof-of-concept work at UC Berkeley’s Bakar Bio Labs while advancing applications in lysosomal storage disorders.
Funding
Amount
$100.0K
Total raised
Date
July 10, 2025
Announcement date
Investors
-
Lead investors
Company
dogmabiotech.bio
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected